The Oxford-Harrington Rare Disease Centre Symposium 2026 brought together researchers, clinicians, patients, policymakers, biopharmaceutical leaders, philanthropists, and advocates to explore the future of rare disease drug development.
The message throughout the meeting was clear: progress is accelerating.
From Discovery to Development
In his opening remarks, Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre, highlighted the Centre's growing impact and expanding therapeutic portfolio.
Today, the Oxford-Harrington Rare Disease Centre supports:
These programs reflect the Centre's unique model, combining philanthropic investment, academic innovation, and hands-on drug development expertise to help move discoveries toward patients.
The symposium featured advances in gene therapy, genome editing, RNA therapeutics, individualized medicines, rare cancers, and new approaches to patient access.
A Model Driven by Philanthropy and Entrepreneurship
The Oxford-Harrington Rare Disease Centre was built on the belief that scientific discoveries deserve a pathway to patients.
That vision stems from the legacy of the Harrington family and the entrepreneurial approach that defines Harrington Discovery Institute at University Hospitals. Through philanthropy, industry expertise, and strategic partnerships, the Centre bridges the gap between academic research and drug development.
The partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals demonstrates how philanthropy can create the infrastructure, expertise, and collaboration required to accelerate new medicines for rare disease patients.
Science, Policy, and Patient Impact
A symposium highlight was a conversation between Lord David Cameron, Former UK Prime Minister, and Chair of the Oxford-Harrington Rare Disease Centre Advisory Council, and Sir John Bell, Emeritus Regius Professor of Medicine at the University of Oxford, and member of Oxford-Harrington's Advisory Council.
Their discussion focused on progress toward new rare disease medicines, the growing impact of genomics, and the role of emerging technologies such as artificial intelligence in accelerating therapeutic development. They emphasized that scientific breakthroughs only matter if they can be translated into treatments that reach patients.
This focus on patient impact remained central throughout the symposium.
Collaboration Across the Rare Disease Ecosystem
The program featured leading voices from academia, government, industry, patient advocacy organizations, and investment groups.
Notable presentations included Professor John Letterio of the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals, who shared innovative work exploring how immune responses generated during COVID-19 infection may be harnessed to fight rare cancers.
The symposium also welcomed philanthropist and advocate Char Fowler, whose longstanding commitment to supporting research and improving outcomes for children and young adults with cancer continues to inspire new opportunities for collaboration.
A panel moderated by Financial Times science editor Clive Cookson explored challenges and opportunities related to translation, commercialization, reimbursement, and patient access. Additional sessions featured leaders from the University of Oxford, University Hospitals, global biopharmaceutical companies, regulatory agencies, and patient organizations.
Expanding Areas of Impact
The symposium highlighted several significant developments fueling future growth, including:
Together, these initiatives demonstrate how philanthropy continues to accelerate scientific progress and therapeutic development.
Amplifying the Mission Through Media Coverage
The symposium generated significant international media attention, further elevating awareness of rare disease research and the Oxford-Harrington mission.
Highlights included:
Endpoint News
BioWorld
BioTech TV
Video interviews featuring
Looking Ahead
The Oxford-Harrington Rare Disease Centre was founded on a simple but ambitious idea: combining philanthropy, entrepreneurship, scientific excellence, and drug development expertise can accelerate new medicines for patients with rare diseases.
For patients and families living with rare disease, every therapy advanced represents another step toward new treatment options and a brighter future.
Lord David Cameron, Former UK Prime Minister and Chair of the Oxford-Harrington Rare Disease Centre Advisory Board, with Sir John Bell, Professor Emeritus, University of Oxford, and member of the Oxford-Harrington Rare Disease Centre Advisory Board
Panel discussion during the Oxford-Harrington Rare Disease Centre Symposium
Attendees gather outdoors for conversation during a networking break at the Oxford-Harrington Rare Disease Centre Symposium